-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Stroke is a leading cause of death and long-term disability and has become a major public health problem worldwide
.
Of all complications in stroke survivors, post-stroke depression (PSD) is the most common psychiatric problem
Stroke In 2005, a systematic review by Hackett et al.
The cohort study included 1221 patients recruited in Australia, New Zealand and Vietnam within 2 weeks of stroke onset
.
Stroke severity was assessed using the NIH Stroke Scale (NIHSS)
diagnosis
RESULTS: The mean age of the participants was 63.
8 (SD 12.
3) years, and 775 (63.
5%) were male
.
At baseline, 48 (3.
Overall, increased stroke severity, such as doubling of the NIHSS score, was associated with early (RR=2.
08, 95%CI 1.
65-2.
62), late (RR=1.
53, 95%CI 1.
14-2.
06) and persistent (RR=2.
08, 95%CI 1.
65-2.
62) stroke severity =2.
50, 95%CI 1.
89-3.
32) were associated with a 108%, 53% and 150% increased risk of clinically significant depressive symptoms, respectively
.
Similar findings were evident in mRS, a measure of dysfunction
Increased stroke severity, such as doubling of the NIHSS score, was associated with early (RR=2.
In addition, past depression was associated with an increased risk of persistent clinically significant depressive symptoms (RR=6.
28, 95%CI 2.
88-13.
71), as was married or partnered individuals (RR=3.
94, 95%CI 2.
42- 6.
41)
.
Taken together, the severity of neurological and functional impairment increases the risk of developing clinically significant depressive symptoms after stroke and is persistent
.
.
Taken together, the severity of neurological and functional impairment increases the risk of developing clinically significant depressive symptoms after stroke and is persistent
references:
Measures Associated With Early, Late, and Persistent Clinically Significant Symptoms of Depression 1 Year After Stroke in the AFFINITY Trial.
Measures Associated With Early, Late, and Persistent Clinically Significant Symptoms of Depression 1 Year After Stroke in the AFFINITY Trial.
Leave a Comment here
